Insider Transactions in Q4 2025 at Cogent Biosciences, Inc. (COGT)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 26
2025
|
John Edward Robinson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
90,000
-39.13%
|
$3,420,000
$38.74 P/Share
|
|
Dec 26
2025
|
Jessica Sachs Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
82,642
-38.16%
|
$3,140,396
$38.7 P/Share
|
|
Dec 26
2025
|
John L. Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
77,000
-36.87%
|
$2,926,000
$38.68 P/Share
|
|
Dec 26
2025
|
Evan Kearns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
65,000
-37.27%
|
$2,470,000
$38.7 P/Share
|
|
Dec 17
2025
|
John L. Green Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
145,007
-40.98%
|
$5,655,273
$39.45 P/Share
|
|
Dec 17
2025
|
John L. Green Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+47.02%
|
-
|
|
Dec 17
2025
|
Jessica Sachs Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
154,716
-41.67%
|
$6,033,924
$39.45 P/Share
|
|
Dec 17
2025
|
Jessica Sachs Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
370,000
+47.83%
|
-
|
|
Dec 17
2025
|
Evan Kearns Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
125,602
-41.87%
|
$4,898,478
$39.45 P/Share
|
|
Dec 17
2025
|
Evan Kearns Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+48.21%
|
-
|
|
Dec 17
2025
|
Cole Pinnow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
94,800
-30.44%
|
$3,697,200
$39.45 P/Share
|
|
Dec 17
2025
|
Cole Pinnow Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
264,000
+37.32%
|
-
|
|
Dec 17
2025
|
Andrew R Robbins President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
367,497
-35.85%
|
$14,332,383
$39.45 P/Share
|
|
Dec 17
2025
|
Andrew R Robbins President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,025,000
+47.52%
|
-
|
|
Dec 17
2025
|
John Edward Robinson Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
139,998
-37.84%
|
$5,459,922
$39.45 P/Share
|
|
Dec 17
2025
|
John Edward Robinson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
370,000
+48.19%
|
-
|